Document is current

Article History

Received: 5 March 2017

Accepted: 7 June 2018

First Online: 10 August 2018

Competing interests

: In the last 12 months Dr. Kurt Schalper has been speaker or consultant for Merck, Takeda Pharmaceuticals, Shattuck Labs and Celgene. His laboratory has received research funding from Vasculox/Tioma, Navigate Biopharma, Tesaro Inc, Onkaido Therapeutics/Moderna, Takeda Pharmaceuticals and Surface Oncology. Dr. David Rimm is consultant or advisor to AstraZeneca, Agendia, Agilent, Biocept, Bristo-Myers-Squibb, Cell Signaling Technology. Cepheid, Merck, Optrascan, Perkinelmer and Ultivue. His laboratory has received research funding from AstraZeneca, Cepheid, Navigate/Novartis, NextCure, Gilead Sciences, Ultivue and Perkinelmer. Dr. Rimm also holds equity in PixelGear. Dr. Katerina Politi serves as consultant or advisor for AstraZeneca, Merck, Novartis and Tocagen. Her laboratory received research funds from AstraZeneca, Roche, Kolltan and Symphogen. Dr. Politi also holds royalties in IP licenced from Memorial Sloan Kettering Cancer Center to Molecular MD. Dr. Sarah Goldberg serves as consultant or advisor for AstraZeneca, Bristol-Myers Squibb, Lilly and Boehringer Ingelheim. She received research support from AstraZeneca. Lieping Chen serves as consultant or advisor for Pfizer, Vcanbio and GenomiCare. He is a scientific founder of NextCure and Tayu Biotech. His laboratory receives research funding from NextCure. The remaining authors declare no competing interests. with the content of this work.